NASDAQ: CINGCingulate Inc Stock
$3.93+0.02 (+0.51%)
Updated Sep 16, 2025
CING Price
$3.93
Fair Value Price
$1.87
Market Cap
$21.27M
52 Week Low
$3.02
52 Week High
$6.01
P/E
-0.96x
P/B
3.86x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$17.96M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.44
Operating Cash Flow
-$17M
Beta
0.99
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CING Overview
Cingulate Inc. is a clinical-stage biopharmaceutical company developing treatments for attention deficit/hyperactivity disorder. The company's lead candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). CTx-2103 is being developed for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, KS.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CING's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CING
Ranked#417 of 479
Ranked#417 of 479
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.87 | A | |
| $34.98 | A | |
| $7.75 | A |
Be the first to know about important CING news, forecast changes, insider trades & much more!
CING News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CING scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CING ($3.93) is overvalued by 110.64% relative to our estimate of its Fair Value price of $1.87 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CING ($3.93) is not significantly undervalued (110.64%) relative to our estimate of its Fair Value price of $1.87 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CING is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CING due diligence checks available for Premium users.
Valuation
CING fair value
Fair Value of CING stock based on Discounted Cash Flow (DCF)
Price
$3.93
Fair Value
$1.87
Overvalued by
110.64%
CING ($3.93) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CING ($3.93) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CING is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CING price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.96x
Industry
-95.43x
Market
37.55x
CING price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.86x
Industry
4.68x
CING is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CING's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.8M
Profit Margin
0%
CING's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$13.5M
Liabilities
$8.0M
Debt to equity
1.44
CING's short-term assets ($10.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CING's short-term assets ($10.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CING's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.8M
Investing
-$5.9k
Financing
$4.2M
CING's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CING vs Biotech Stocks
Cingulate Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.